Boxer Capital BOLD Position
ExitedBoxer Capital exited their position in Boundless Bio, Inc. (BOLD) in Q4 2024, after holding the stock for 4 quarters.
The position was first reported in Q1 2024 and has been tracked across 4 quarterly 13F filings.
2 other tracked funds also hold BOLD.
About Boundless Bio, Inc.
Boundless Bio, Inc., a clinical-stage oncology company, develops cancer therapeutics to address the unmet need of patients with oncogene amplified tumors by targeting extrachromosomal DNA. Its lead product candidate is BBI-355, an oral inhibitor of checkpoint kinase 1 that is in Phase 1/2 clinical trial in patients with oncogene amplified cancers. The company is also developing BBI-825, an oral inhibitor of ribonucleotide reductase, which is in Phase 1/2 clinical trial in cancer patients with resistance gene amplifications; and ecDTx 3 program targeting a kinesin involved with the cellular mechanism for segregation of ecDNA. Boundless Bio, Inc. was formerly known as Pretzel Therapeutics, Inc. and changed its name to Boundless Bio, Inc. in July 2019. The company was incorporated in 2018 and is headquartered in San Diego, California.
Full company profile →Short Interest
0.1%
0.1 days to cover
Boxer Capital BOLD Position History
Frequently Asked Questions
Does Boxer Capital own BOLD?
No. Boxer Capital exited their position in Boundless Bio, Inc. (BOLD) in Q4 2024. They previously held the stock for 4 quarters.
How many hedge funds own BOLD?
2 specialist biotech hedge funds currently hold BOLD, including Redmile Group, RA Capital Management. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Boxer Capital first buy BOLD?
Boxer Capital's position in BOLD was first reported in Q1 2024. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Boxer Capital's BOLD position increasing or decreasing?
Boxer Capital completely exited their BOLD position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
BOLDCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Boxer CapitalPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →